Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Clinical Genetics

Navigating the Path to a Diagnosis

At a Glance

Doctors diagnose Nakajo-Nishimura syndrome by combining early fevers, characteristic skin rashes, progressive loss of fat and muscle, and broad genetic testing. An interferon score can support the diagnosis but cannot confirm NNS on its own.

Getting to a diagnosis of Nakajo-Nishimura Syndrome (NNS) is often described as a “diagnostic odyssey.” Because it is so rare, it is common for families to spend years seeing different specialists before the pieces of the puzzle—fevers, skin rashes, and fat loss—are finally connected [1][2]. Doctors today rely on a combination of clinical pattern recognition, specialized blood work, and advanced genetic testing to evaluate the diagnosis [3].

The Clinical Pattern: The First Clue

The most important tool a doctor has is the medical history. Specialists look for a specific “signature” of symptoms that appear very early in life, often before age one [1]. This includes:

  • Recurrent or persistent fevers [2].
  • Rashes that look like chilblains (pernio-like) or tender red bumps (panniculitic nodules) [1][4].
  • The progressive loss of fat and muscle, especially in the face and upper body [1].
  • Joint stiffness or fingers that appear long and rounded at the tips (clubbing) [4].

The Role of Genetics

While classic NNS is caused by biallelic mutations (inheriting a mutation from both parents) in the PSMB8 gene, we now know that variants in several other genes can cause nearly identical symptoms [1][5].

  • Genetic Panels: Instead of testing just one gene, doctors now recommend using a broad autoinflammatory panel or whole-exome sequencing. This ensures they don’t miss variants in other proteasome-related genes like PSMB9, PSMB4, PSMB10, or POMP, which cause different conditions under the broader PRAAS umbrella [5][6][7].
  • Inheritance Patterns: Because some variants are of “uncertain significance” (VUS) or have different inheritance patterns (dominant or digenic), interpreting the results requires a clinical geneticist or genetic counselor [6][8]. They can discuss recurrence risks, parental carrier testing, and whether siblings should be evaluated.

The Type I Interferon Signature

A breakthrough in evaluating NNS and other PRAAS conditions is the Type I interferon signature (or interferon score) [6].

Interferons are proteins your immune system uses to fight viruses. In conditions like NNS, the body acts as if it is fighting a permanent virus, even when none is present [6]. Some specialized centers measure this by looking at a specific set of 28 genes in the blood [9]. An elevated score supports the presence of an interferonopathy [6]. While this score is a supportive biomarker, it isn’t a definitive “yes or no” for NNS specifically—other infections or inflammatory conditions can also cause high scores [10].

Look-Alike Conditions

Because the symptoms of NNS can overlap with other diseases, your doctor must rule out “look-alikes,” including:

  • SAVI (STING-Associated Vasculopathy with Onset in Infancy): Also has an interferon signature but often involves severe lung disease and more significant skin ulcers [11][12].
  • Juvenile Dermatomyositis: Causes muscle weakness and skin rashes but typically shows different markers in the blood (like high CK enzymes).
  • Lupus (SLE): Can share skin and joint symptoms, but specific autoantibody tests and a careful clinical synthesis help distinguish it [12].

Diagnosis Completeness Checklist

If you are currently in the middle of a diagnostic workup, ensure your medical team has completed or considered the following:

Test Category What to Look For Why It Matters
Genetic Panel Broad panel (including PSMB8, PSMB9, POMP, etc.) Missing one gene could lead to a “negative” result in someone who actually has a PRAAS condition [5].
Interferon Score Standardized signature (if available) Supports the “interferonopathy” status, though not universally required for diagnosis [9].
Inflammatory Markers CRP, ESR, and Ferritin Measures the overall level of active inflammation in the body [2].
Targeted Imaging Ultrasounds or MRIs Ordered only if specific physical or neurological symptoms warrant investigating organ size or joints. Routine brain CTs are avoided to limit radiation [4][2].
Biopsy (Optional) Skin or muscle biopsy Usually not needed for the final diagnosis, but can help rule out other “look-alikes” if the genetics are unclear [13][2].

Confirming the diagnosis is a significant milestone. It moves you from “searching for answers” to “planning for treatment” [3].

Common questions in this guide

How is Nakajo-Nishimura syndrome diagnosed?
Doctors look for a pattern that usually begins in infancy, including recurrent fevers, chilblain-like or tender skin rashes, and progressive loss of fat and muscle. They combine the medical history and examination with inflammatory blood tests and genetic testing; no single test confirms NNS in every case.
What genes are tested when NNS is suspected?
Classic NNS is linked to disease-causing changes in both copies of the PSMB8 gene. A broad autoinflammatory gene panel or whole-exome sequencing may also assess PSMB9, PSMB4, PSMB10, and POMP because changes in these genes can cause related proteasome-associated inflammatory syndromes.
What does an interferon score tell you about NNS?
An elevated type I interferon signature supports an interferon-related inflammatory disorder by showing increased activity in interferon-responsive genes. It does not prove NNS by itself, because infections and other inflammatory diseases can also raise the score.
Can NNS look like other diseases?
Yes. SAVI, juvenile dermatomyositis, lupus, and some infections can cause overlapping rashes, inflammation, and muscle or joint symptoms. Doctors compare the skin findings, lung and muscle involvement, blood markers, and genetic results to distinguish these conditions.
What does a variant of uncertain significance mean on an NNS genetic test?
A variant of uncertain significance is a genetic change whose health effect is not yet clear, so it usually cannot confirm or exclude NNS on its own. A clinical geneticist or genetic counselor may review the family pattern and offer parental or sibling testing when appropriate.
Are imaging or biopsy always needed to diagnose NNS?
No. Ultrasound or MRI is generally considered when specific organ, joint, or neurologic symptoms need evaluation, while routine brain CT is avoided when possible to limit radiation. Skin or muscle biopsy is optional and may help rule out other conditions when genetic results are unclear.

Get notified when new evidence is published on Nakajo-Nishimura syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Nakajo-Nishimura syndrome and related proteasome-associated autoinflammatory syndromes.

    Ohmura K

    Journal of inflammation research 2019; (12()):259-265 doi:10.2147/JIR.S194098.

    PMID: 31576159
  2. 2

    Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome: A Systemic Review.

    Altom A, Khader SAE, Gad AG, et al.

    The American Journal of dermatopathology 2023; (45(6)):355-370 doi:10.1097/DAD.0000000000002345.

    PMID: 37191371
  3. 3

    The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.

    Cetin Gedik K, Lamot L, Romano M, et al.

    Annals of the rheumatic diseases 2022; (81(5)):601-613 doi:10.1136/annrheumdis-2021-221814.

    PMID: 35086813
  4. 4

    A Chinese case of Nakajo-Nishimura syndrome with novel compound heterozygous mutations of the PSMB8 gene.

    Jia T, Zheng Y, Feng C, et al.

    BMC medical genetics 2020; (21(1)):126 doi:10.1186/s12881-020-01060-8.

    PMID: 32513120
  5. 5

    Contribution of the Unfolded Protein Response (UPR) to the Pathogenesis of Proteasome-Associated Autoinflammatory Syndromes (PRAAS).

    Ebstein F, Poli Harlowe MC, Studencka-Turski M, Krüger E

    Frontiers in immunology 2019; (10()):2756 doi:10.3389/fimmu.2019.02756.

    PMID: 31827472
  6. 6

    Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.

    Brehm A, Liu Y, Sheikh A, et al.

    The Journal of clinical investigation 2015; (125(11)):4196-211.

    PMID: 26524591
  7. 7

    Identification of eight novel proteasome variants in five unrelated cases of proteasome-associated autoinflammatory syndromes (PRAAS).

    Papendorf JJ, Ebstein F, Alehashemi S, et al.

    Frontiers in immunology 2023; (14()):1190104 doi:10.3389/fimmu.2023.1190104.

    PMID: 37600812
  8. 8

    Monoallelic PSMB8 variants cause PRAAS with immunodeficiency through impaired immunoproteasome assembly.

    Wijngaard R, van der Made CI, Kalkan Uçar S, et al.

    American journal of human genetics 2026; (113(6)):1214-1232 doi:10.1016/j.ajhg.2026.04.015.

    PMID: 42167218
  9. 9

    Development of a Validated Interferon Score Using NanoString Technology.

    Kim H, de Jesus AA, Brooks SR, et al.

    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2018; (38(4)):171-185 doi:10.1089/jir.2017.0127.

    PMID: 29638206
  10. 10

    Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.

    de Jesus AA, Hou Y, Brooks S, et al.

    The Journal of clinical investigation 2020; (130(4)):1669-1682.

    PMID: 31874111
  11. 11

    Vasculitis in Systemic Autoinflammatory Diseases.

    Demir S, Sag E, Dedeoglu F, Ozen S

    Frontiers in pediatrics 2018; (6()):377 doi:10.3389/fped.2018.00377.

    PMID: 30560109
  12. 12

    Unraveling the diagnostic odyssey: stimulator of interferon gene-associated vasculopathy with onset in infancy in a 30-year-old female.

    Kim HR, Lim SH, Park JS, et al.

    Journal of rheumatic diseases 2024; (31(3)):182-187 doi:10.4078/jrd.2023.0075.

    PMID: 38957365
  13. 13

    Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy.

    Ayaki T, Murata K, Kanazawa N, et al.

    Neuropathology and applied neurobiology 2020; (46(6)):579-587 doi:10.1111/nan.12614.

    PMID: 32144790

This page explains how clinicians evaluate suspected Nakajo-Nishimura syndrome for educational purposes and does not constitute medical advice. A clinical geneticist, genetic counselor, or treating specialist should interpret individual results and recommend testing.